Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 6Glioma 6Glioblastoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Melanoma 4Breast Neoplasms 4Sarcoma 3Prostatic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Pancreatic Ductal Adenocarcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Immunoglobulin Light-chain Amyloidosis 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Basal Cell 2Burkitt Lymphoma 2Brain Neoplasms 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1

Interventions

prednylidene 1deltacortene 1daratumumab 1Vincristine 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Plasmablastic Lymphoma × 30 days × Clear all
NCT04139304 2026-06-01

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

AIDS Malignancy Consortium

Phase EARLY_PHASE1 Recruiting
15 enrolled
Lymphoid

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡